127 related articles for article (PubMed ID: 10975836)
41. Presentation on class II MHC molecules of endogenous lysozyme targeted to the endocytic pathway.
Parra-López CA; Lindner R; Vidavsky I; Gross M; Unanue ER
J Immunol; 1997 Mar; 158(6):2670-9. PubMed ID: 9058800
[TBL] [Abstract][Full Text] [Related]
42. Co-dominant restriction by a mixed-haplotype I-A molecule (alpha k beta b) for the lysozyme peptide 52-61 in H-2k x H-2b F1 mice.
Moreno J; Adorini L; Hämmerling GJ
J Immunol; 1990 May; 144(9):3296-304. PubMed ID: 1970351
[TBL] [Abstract][Full Text] [Related]
43. Effects of pH and polysaccharides on peptide binding to class II major histocompatibility complex molecules.
Harding CV; Roof RW; Allen PM; Unanue ER
Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2740-4. PubMed ID: 2011583
[TBL] [Abstract][Full Text] [Related]
44. Distinct effects of recombinant cholera toxin B subunit and holotoxin on different stages of class II MHC antigen processing and presentation by macrophages.
Matousek MP; Nedrud JG; Harding CV
J Immunol; 1996 Jun; 156(11):4137-45. PubMed ID: 8666780
[TBL] [Abstract][Full Text] [Related]
45. Cutting edge: introduction of an endopeptidase cleavage motif into a determinant flanking region of hen egg lysozyme results in enhanced T cell determinant display.
Schneider SC; Ohmen J; Fosdick L; Gladstone B; Guo J; Ametani A; Sercarz EE; Deng H
J Immunol; 2000 Jul; 165(1):20-3. PubMed ID: 10861030
[TBL] [Abstract][Full Text] [Related]
46. Presentation of antigens internalized through the B cell receptor requires newly synthesized MHC class II molecules.
Forquet F; Barois N; Machy P; Trucy J; Zimmermann VS; Leserman L; Davoust J
J Immunol; 1999 Mar; 162(6):3408-16. PubMed ID: 10092796
[TBL] [Abstract][Full Text] [Related]
47. Analysis of T cell reactivities to phosphorylcholine-conjugated hen egg lysozyme in C57BL/6 mice: hapten-conjugate specificity reflects an altered expression of a major carrier epitope.
Jang YS; Lim KH; Kim BS
Eur J Immunol; 1991 May; 21(5):1303-10. PubMed ID: 1709872
[TBL] [Abstract][Full Text] [Related]
48. Class II-restricted presentation of a hen egg lysozyme determinant derived from endogenous antigen sequestered in the cytoplasm or endoplasmic reticulum of the antigen presenting cells.
Brooks AG; McCluskey J
J Immunol; 1993 May; 150(9):3690-7. PubMed ID: 8473726
[TBL] [Abstract][Full Text] [Related]
49. Insertion of the dibasic motif in the flanking region of a cryptic self-determinant leads to activation of the epitope-specific T cells.
Zhu H; Liu K; Cerny J; Imoto T; Moudgil KD
J Immunol; 2005 Aug; 175(4):2252-60. PubMed ID: 16081793
[TBL] [Abstract][Full Text] [Related]
50. Activated antigen-presenting cells select and present chemically modified peptides recognized by unique CD4 T cells.
Herzog J; Maekawa Y; Cirrito TP; Illian BS; Unanue ER
Proc Natl Acad Sci U S A; 2005 May; 102(22):7928-33. PubMed ID: 15901898
[TBL] [Abstract][Full Text] [Related]
51. Single amino acid mutations in the murine MHC class II A beta cytoplasmic domain abrogate antigen presentation.
Laufer TM; Smiley ST; Ranger A; Clements VK; Ostrand-Rosenberg S; Glimcher LH
J Immunol; 1997 Dec; 159(12):5914-20. PubMed ID: 9550388
[TBL] [Abstract][Full Text] [Related]
52. Antigenic competition at the level of peptide-Ia binding.
Babbitt BP; Matsueda G; Haber E; Unanue ER; Allen PM
Proc Natl Acad Sci U S A; 1986 Jun; 83(12):4509-13. PubMed ID: 3459185
[TBL] [Abstract][Full Text] [Related]
53. Following immunization antigen becomes concentrated in a limited number of APCs including B cells.
Byersdorfer CA; Dipaolo RJ; Petzold SJ; Unanue ER
J Immunol; 2004 Dec; 173(11):6627-34. PubMed ID: 15557153
[TBL] [Abstract][Full Text] [Related]
54. Binding to Ia protects an immunogenic peptide from proteolytic degradation.
Donermeyer DL; Allen PM
J Immunol; 1989 Feb; 142(4):1063-8. PubMed ID: 2783704
[TBL] [Abstract][Full Text] [Related]
55. Dose-dependent T cell tolerance to an immunodominant self peptide.
Cabaniols JP; Cibotti R; Kourilsky P; Kosmatopoulos K; Kanellopoulos JM
Eur J Immunol; 1994 Aug; 24(8):1743-9. PubMed ID: 8056033
[TBL] [Abstract][Full Text] [Related]
56. The mode of protein antigen administration determines preferential presentation of peptide-class II complexes by lymph node dendritic or B cells.
Guéry JC; Ria F; Galbiati F; Smiroldo S; Adorini L
Int Immunol; 1997 Jan; 9(1):9-15. PubMed ID: 9043943
[TBL] [Abstract][Full Text] [Related]
57. mAb against hen egg-white lysozyme regulate its presentation to CD4(+) T cells.
Guermonprez P; Lo-Man R; Sedlik C; Rojas MJ; Poljak RJ; Leclerc C
Int Immunol; 1999 Nov; 11(11):1863-72. PubMed ID: 10545490
[TBL] [Abstract][Full Text] [Related]
58. Crystal structure of I-Ak in complex with a dominant epitope of lysozyme.
Fremont DH; Monnaie D; Nelson CA; Hendrickson WA; Unanue ER
Immunity; 1998 Mar; 8(3):305-17. PubMed ID: 9529148
[TBL] [Abstract][Full Text] [Related]
59. Amino-terminal trimming of peptides for presentation on major histocompatibility complex class II molecules.
Nelson CA; Vidavsky I; Viner NJ; Gross ML; Unanue ER
Proc Natl Acad Sci U S A; 1997 Jan; 94(2):628-33. PubMed ID: 9012835
[TBL] [Abstract][Full Text] [Related]
60. Hindrance of binding to class II major histocompatibility complex molecules by a single amino acid residue contiguous to a determinant leads to crypticity of the determinant as well as lack of response to the protein antigen.
Grewal IS; Moudgil KD; Sercarz EE
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1779-83. PubMed ID: 7533299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
